PortlandTribune.com
2 months agoMedicine
Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU
Approximately half of metastatic breast cancer patients express low HER2 levels, making them eligible for HER2-targeted treatment.
The VENTANA HER2 (4B5) test is approved to identify HER2-low status in metastatic breast cancer patients for targeted treatment. [ more ]